Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models [CUT&RUN]

ABSTRACT: Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models [CUT&RUN]

PROVIDER: PRJNA1003911 | ENA |

REPOSITORIES: ENA